跳轉至內容
Merck
全部照片(1)

文件

S9509

Supelco

(±)-磺吡酮

analytical standard

同義詞:

1,2-二苯基-4-(苯亚砜基乙基)-3,5-吡咯烷二酮, 二苯基吡嗪酮

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C23H20N2O3S
CAS號碼:
分子量::
404.48
EC號碼:
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

analytical standard

品質等級

化驗

≥99%

技術

HPLC: suitable
gas chromatography (GC): suitable

應用

cleaning products
cosmetics
food and beverages
forensics and toxicology
personal care
pharmaceutical (small molecule)
veterinary

格式

neat

SMILES 字串

O=C1C(CCS(=O)c2ccccc2)C(=O)N(N1c3ccccc3)c4ccccc4

InChI

1S/C23H20N2O3S/c26-22-21(16-17-29(28)20-14-8-3-9-15-20)23(27)25(19-12-6-2-7-13-19)24(22)18-10-4-1-5-11-18/h1-15,21H,16-17H2

InChI 密鑰

MBGGBVCUIVRRBF-UHFFFAOYSA-N

基因資訊

尋找類似的產品? 前往 產品比較指南

一般說明

磺吡酮是一种1,3-二羰基尿酸尿酸药物,可用于治疗与痛风有关的高尿酸血症。

應用

有关合适仪器技术的更多信息,请参考产品分析证书。如需进一步支持,请联系技术服务。

象形圖

Exclamation mark

訊號詞

Warning

危險聲明

危險分類

Acute Tox. 4 Oral

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable

個人防護裝備

dust mask type N95 (US), Eyeshields, Faceshields, Gloves


Choose from one of the most recent versions:

分析證明 (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Screening of xanthine oxidase inhibitor from selected edible plants and hypouricemic effect of Rhizoma Alpiniae Officinarum extract on hyperuricemic rats
Lin L, et al.
Journal of functional foods, 50(1), 26-36 (2018)
High-performance liquid chromatography-tandem mass spectrometry in the identification and determination of phase I and phase II drug metabolites
Holcapek M, et al.
Analytical and Bioanalytical Chemistry, 391(1), 59-78 (2008)
Sulfinpyrazone C-glucuronidation is catalyzed selectively by human UDP-glucuronosyltransferase 1A9 (UGT1A9)
Kerdpin O, et al.
Drug Metabolism and Disposition, 50(1), 26-36 (2006)
D H Solomon et al.
Annals of the rheumatic diseases, 67(5), 609-613 (2007-08-31)
Uric acid lowering therapy (UALT) is considered a chronic treatment for gout. Relatively little is known about adherence to UALT. We assessed adherence with UALT over a 1-year study period among 9823 older adults enrolled in a pharmacy benefit program.
Leslie R Harrold et al.
Arthritis research & therapy, 11(2), R46-R46 (2009-03-31)
Adherence to urate-lowering drugs (ULDs) has not been well evaluated among those with gout. Our aim was to assess the level and determinants of non-adherence with ULDs prescribed for gout. We identified persons using two integrated delivery systems aged 18

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務